Delivering the precision oncology paradigm: reduced R&D costs and greater return on investment through a companion diagnostic informed precision oncology medicines approach. (2023)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1186/s40545-023-00590-9
PubMed Identifier: 37408046
Publication URI: http://europepmc.org/abstract/MED/37408046
Type: Journal Article/Review
Volume: 16
Parent Publication: Journal of pharmaceutical policy and practice
Issue: 1
ISSN: 2052-3211